Insider Selling: 908 Devices Inc. (NASDAQ:MASS) Insider Sells 9,672 Shares of Stock

908 Devices Inc. (NASDAQ:MASS) insider Michael S. Turner sold 9,672 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.33, for a total value of $22,535.76. Following the completion of the transaction, the insider now directly owns 24,603 shares of the company’s stock, valued at $57,324.99. This trade represents a 28.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

908 Devices Stock Up 11.8 %

Shares of MASS stock opened at $2.65 on Thursday. The stock has a 50-day simple moving average of $2.35 and a 200 day simple moving average of $3.26. The stock has a market capitalization of $92.27 million, a P/E ratio of -1.50 and a beta of 0.98. 908 Devices Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $7.91.

Hedge Funds Weigh In On 908 Devices

Several large investors have recently made changes to their positions in MASS. Concurrent Investment Advisors LLC bought a new stake in shares of 908 Devices in the 4th quarter worth approximately $52,000. B. Riley Wealth Advisors Inc. bought a new stake in 908 Devices during the third quarter worth approximately $45,000. Barclays PLC grew its position in 908 Devices by 452.7% in the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock worth $160,000 after buying an additional 37,853 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of 908 Devices by 1.2% in the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock valued at $1,970,000 after buying an additional 6,634 shares in the last quarter. Finally, State Street Corp lifted its position in shares of 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock valued at $1,662,000 after acquiring an additional 5,704 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Stifel Nicolaus decreased their price target on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Stephens reaffirmed an “overweight” rating and issued a $6.00 price objective on shares of 908 Devices in a report on Wednesday, January 15th. Leerink Partnrs cut shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday, February 1st. Finally, Leerink Partners reiterated a “market perform” rating and issued a $4.00 price objective (down from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.